RNTX Stock Analysis: Buy, Sell, or Hold?
RNTX - Rein Therapeutics, Inc. Common Stock
$0.79
0.04 (5.32%)
▲
5d:
+0.43%
30d:
-23.77%
90d:
-23.02%
BUY
MODERATE Confidence
Analysis Updated: Aug 3, 2026 12:00 AM ET
Earnings: Aug 13, 2026
8d
Get Alerted When RNTX Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
💡 BUY OPPORTUNITY: RNTX shows positive signals but monitor for confirmation. Company currently unprofitable (negative forward earnings). Moderate conviction.
💡 BUY OPPORTUNITY: RNTX shows positive signals but monitor for confirmation. Company currently unprofitable (negative forward earnings). Moderate conviction.
In-depth Analysis How we analyze
Valuation Analysis: RNTX is currently trading at $0.79, which is considered oversold relative to its 30-day fair value range of $0.79 to $0.99.
Technical Outlook: Technically, RNTX is in a strong downtrend. Immediate support is located at $0.72, while resistance sits at $0.93. The stock is showing strong short-term momentum, up 5.3% recently.
Market Sentiment: RNTX has a weak technical setup (25/100), with bearish trendlines and momentum suggesting caution for short-term entries. Wall Street analysts see significant upside, with an average price target of $6.00 (+704.8%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Technical Outlook: Technically, RNTX is in a strong downtrend. Immediate support is located at $0.72, while resistance sits at $0.93. The stock is showing strong short-term momentum, up 5.3% recently.
Market Sentiment: RNTX has a weak technical setup (25/100), with bearish trendlines and momentum suggesting caution for short-term entries. Wall Street analysts see significant upside, with an average price target of $6.00 (+704.8%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Quick Decision Summary
Current Position
OVERSOLD
Historical Trading Range
$0.79 -
$0.99
Company Quality Score
42/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
63.2%
All Signals
- BULLISH: Price oversold vs 30-day range
- BEARISH: Weak technical setup (25/100)
- BULLISH: High volume confirmation
- BULLISH: Strong upward momentum (+5.3%)
- BULLISH: Trading 704.8% below Wall St target ($6.00)
Trading Range Analysis
30-Day Trading Range
$0.79 -
$0.99
Current vs Trading Range
OVERSOLD
Support & Resistance Levels
Support Level
$0.73
Resistance Level
$0.93
Current Trend
Strong Downtrend
Technical data as of
Aug 3, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-1.82
Wall Street Target
$6.00
(+704.8%)
Share & Embed Analysis
Last updated: August 04, 2026 12:32 PM ET
Data refreshes hourly during market hours. Next update: 1:32 PM
Data refreshes hourly during market hours. Next update: 1:32 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is RNTX showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
ARGX
argenx NV ADR |
STRONG BUY
22 analysts |
$1080 | 57 HOLD |
|
SRPT
Sarepta Therapeutics Inc |
STRONG BUY
26 analysts |
$22 | 45 HOLD |
|
LEGN
Legend Biotech Corp |
STRONG BUY
22 analysts |
$52 | 52 HOLD |
|
MRUS
Merus BV |
STRONG BUY
17 analysts |
$97 | 55 HOLD |
|
KYMR
Kymera Therapeutics Inc |
STRONG BUY
20 analysts |
$127 | 54 HOLD |